Full-Time
Architect 1
Appian Automation
Posted on 6/6/2026
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Pune, Maharashtra, India
In Person
 Software Engineering (1) |
|---|
- 11+ years of IT experience in enterprise application design, development, and delivery
- 7–8 years of hands‑on Appian delivery experience in architect/lead roles across large-scale implementations
- 3–4 years of experience designing and implementing AI/ML/LLM or generative AI solutions within enterprise workflows
- Advanced expertise in Appian components: Process Models, Records, Sites, Interfaces, Data Fabric, Processes Portal, Appian RPA, and AI capabilities (Generative AI, AI Document Center, Private LLM)
- Practical experience with Appian Agent Studio (beta or GA) for designing, building, and deploying autonomous agents
- Strong understanding of Appian cloud deployment, scalability, and performance optimization patterns
- Hands-on experience integrating LLM and generative AI services (Azure OpenAI, AWS Bedrock, Google Vertex AI, on‑prem LLMs) into enterprise processes
- Experience architecting multi-agent and agentic automation workflows for complex, multi-step business tasks
- Solid knowledge of prompt engineering, prompt optimization, and responsible AI practices (hallucination mitigation, bias control, guardrails)
- Experience working with Azure cloud services
- Strong database design skills and SQL proficiency
- Educational Requirements: Bachelor’s degree in computer science, Information Technology or any other related discipline or equivalent related experience
- Preferred Certifications: Appian Advanced Developer or Lead Certification (or equivalent Level 2+) –Mandatory
- Skills & Knowledge: Behavioral Skills: Collaboration, Creativity & Innovation, Decision Making, Planning, Presentation Skills, Risk-taking
- Technical Skills: Cloud Architecture, Data Architecture & Governance, Integration Testing and Validation, Operating Systems, Programming and Development, Application Architecture, Software Development Life Cycle (SDLC)
- Tools Knowledge: Architecture Framework tools, Cloud Computing Tools (AWS, Azure, Google Cloud), Integration and Deployment tools (Jenkins, Copado, Azure DevOps)
- Define target‑state architecture for complex Appian solutions integrating processes, RPA, APIs, events, and agentic AI
- Design multi‑agent AI workflows with human‑in‑the‑loop controls for accuracy, compliance, and exception management
- Architect and govern autonomous agents using Appian Agent Studio, ensuring auditability and controlled execution
- Translate business outcomes into Appian + AI solution roadmaps, governance models, and guardrail frameworks
- Establish AI governance covering agent authorization, task routing, approvals, and audit trails
- Implement monitoring and feedback loops to continuously improve agent and model performance
- Set up observability for agent behavior, LLM performance, latency, cost efficiency, and compliance metrics
- Ensure alignment with data governance, security, and regulatory requirements (auditability, explainability, PII handling)
- Provide end‑to‑end technical leadership across architecture, delivery, performance tuning, and production support
- Review and approve designs, integrations, data models, and security frameworks for Appian + AI components
- Lead development teams across Appian Sites, Records, Interfaces, Data Fabric, Agent Studio, AI, and RPA
- Deliver scalable, secure, and high‑quality solutions meeting business and SLA expectations
- Strong proficiency in Python or similar programming languages
- Experience with version control tools (Git/GitHub) and CI/CD pipelines
- Familiarity with application performance monitoring and observability tools
- Working knowledge of Agile/Scrum methodologies and DevOps practices
- Understanding of major compliance frameworks (SOX, HIPAA, PCI‑DSS, GDPR, FedRAMP) and their impact on system design
- Knowledge of business process optimization, intelligent automation ROI, and enterprise process mining
- Hands-on experience with RPA technologies such as UiPath or Blue Prism
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Simplify's Take
What believers are saying
- Specialty pharmaceuticals remain the main growth engine for higher-margin services.
- Management targets $300 million in savings while sustaining about $3 billion free cash flow.
- Share repurchases and accretive acquisitions can support earnings per share.
What critics are saying
- Biosimilar conversions are cutting revenue growth at major mail-order pharmacy customers.
- Manufacturer list-price cuts created a $2 billion quarterly revenue headwind.
- Customer losses and slower GLP-1 growth weaken Cencora's specialty mix.
What makes Cencora unique
- Cencora combines drug distribution, specialty pharmacy, and patient-support services.
- It operates globally, serving manufacturers, providers, pharmacies, and veterinary customers.
- The company is expanding specialty care through OneOncology and EyeSouth retina assets.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Cencora who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.
Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.
Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.
Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.
Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.